Patient Square Capital, a health care investment firm, led a $270m Series C funding round in Kriya Therapeutics, a gene therapy company, with participation from Bluebird Ventures, CAM Capital, Dexcel Pharma, Foresite Capital, JDRF, Lightswitch Capital, Narya Capital, QVT, Transhuman Capital. “Kriya has made tremendous strides over the past few years, attracting world-class talent, expanding its pipeline, and scaling the infrastructure necessary to unlock the full potential of gene therapy. We believe the company has the potential to be the clear leader in the evolving gene therapy field, consistent with Patient Square Capital’s focus to build and support category leading companies in health care,” Jim Momtazee, Patient Square Capital Managing Partner.